Resource id #3DrugId:1d00000044resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   


Drug ID: 1d00000044

Drug Name: Alemtuzumab

Generic Names: Campath

Category: Chemotherapy

Legal Status: Non Opioid Prescription only drug

OTC: No

Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose:

Recommended In: This medication is a monoclonal antibody, prescribed for B-chronic lymphocytic leukemia. It works by activating the immune system to destroy cancer cells.

Directions For Use: IV- With Pre-medication- IV infusion over 2 hours-
Day 1: 3mg
Day 2: 10mg
Day 3: 30mg.

Storage: Store it at room temperature (15-30C) or refrigerate (2-8C). Protect from light.

Dosage Forms: Intravenous injection

Side Effects: Blood and Lymphatic - Abnormal decrease in white blood cells, platelets and anemia.

General - Fever, chills and infections.

Skin - Hives, rash and redness.

Heart - Low blood pressure, high blood pressure and fast heart rate.

Central Nervous System - Headache, tremor, sleeplessness and anxiety.

Respiratory - Difficulty in breathing.

Gastrointestinal - Diarrhea.

In Case of Overdose: Across all clinical experience, the reported maximum single dose received was 90 mg. Bone marrow aplasia, infections, or severe infusions reactions occurred in patients who received a dose higher than recommended.

One patient received an 80 mg dose by IV infusion and experienced acute bronchospasm, cough, and dyspnea, followed by anuria and death. Another patient received two 90 mg doses by IV infusion one day apart during the second week of treatment and experienced a rapid onset of bone marrow aplasia.

There is no known specific antidote for alemtuzumab overdosage. Treatment consists of drug discontinuation and supportive therapy.

Avoid If: Caution should be exercised in patients with history of shingles or chickenpox, high blood pressure, heart disease, or blood vessel problems, severe infection, poor immunity, bone marrow depression, blood transfusion, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.

It may cause drowsiness or dizziness, do not drive a car or operate machinery while taking this medication.
It may reduce platelet counts; avoid injury or bruising.

Avoid live vaccination while taking this medication.

Monitor complete blood counts regularly while taking this medication.

Drug Interaction: No formal drug interaction studies have been performed with alemtuzumab.



Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main